[go: up one dir, main page]

DK1701698T3 - Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 - Google Patents

Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Info

Publication number
DK1701698T3
DK1701698T3 DK04814371T DK04814371T DK1701698T3 DK 1701698 T3 DK1701698 T3 DK 1701698T3 DK 04814371 T DK04814371 T DK 04814371T DK 04814371 T DK04814371 T DK 04814371T DK 1701698 T3 DK1701698 T3 DK 1701698T3
Authority
DK
Denmark
Prior art keywords
cci
pharmaceutical composition
oral administration
directly compressible
compressible pharmaceutical
Prior art date
Application number
DK04814371T
Other languages
English (en)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1701698T3 publication Critical patent/DK1701698T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK04814371T 2004-01-08 2004-12-14 Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779 DK1701698T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
DK1701698T3 true DK1701698T3 (da) 2008-05-05

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04814371T DK1701698T3 (da) 2004-01-08 2004-12-14 Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Country Status (30)

Country Link
US (1) US20050152983A1 (da)
EP (1) EP1701698B1 (da)
JP (1) JP2007517879A (da)
KR (1) KR20060130162A (da)
CN (1) CN1921861A (da)
AR (1) AR047180A1 (da)
AT (1) ATE383859T1 (da)
AU (1) AU2004314213A1 (da)
BR (1) BRPI0418373A (da)
CA (1) CA2552595A1 (da)
CR (1) CR8491A (da)
CY (1) CY1107373T1 (da)
DE (1) DE602004011398T2 (da)
DK (1) DK1701698T3 (da)
EC (1) ECSP066757A (da)
ES (1) ES2298861T3 (da)
GT (1) GT200500003A (da)
HN (1) HN2005000005A (da)
IL (1) IL176519A0 (da)
MX (1) MXPA06007829A (da)
NO (1) NO20062930L (da)
PA (1) PA8621201A1 (da)
PE (1) PE20050683A1 (da)
PL (1) PL1701698T3 (da)
PT (1) PT1701698E (da)
RU (1) RU2006122517A (da)
TW (1) TW200526213A (da)
UA (1) UA84903C2 (da)
WO (1) WO2005070393A2 (da)
ZA (1) ZA200605631B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
BRPI0509852A (pt) * 2004-04-14 2007-10-23 Wyeth Corp método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
RU2007127499A (ru) * 2005-02-15 2009-03-27 Вайет (Us) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
EA015922B1 (ru) 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
MX387669B (es) 2012-06-04 2025-03-18 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2017038925A1 (ja) * 2015-09-03 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
RO120603B1 (ro) * 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
DK1658295T3 (da) * 2003-08-07 2007-09-24 Wyeth Corp Regioselektiv syntese af CCI-779
WO2005023254A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
RU2007127499A (ru) * 2005-02-15 2009-03-27 Вайет (Us) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме

Also Published As

Publication number Publication date
DE602004011398D1 (de) 2008-03-06
MXPA06007829A (es) 2006-09-01
AR047180A1 (es) 2006-01-11
CR8491A (es) 2008-08-21
TW200526213A (en) 2005-08-16
ATE383859T1 (de) 2008-02-15
WO2005070393A3 (en) 2006-09-28
JP2007517879A (ja) 2007-07-05
ES2298861T3 (es) 2008-05-16
GT200500003A (es) 2005-08-18
HN2005000005A (es) 2009-04-17
PA8621201A1 (es) 2005-12-23
ZA200605631B (en) 2010-01-27
CA2552595A1 (en) 2005-08-04
IL176519A0 (en) 2006-10-05
CN1921861A (zh) 2007-02-28
DE602004011398T2 (de) 2009-01-15
RU2006122517A (ru) 2008-02-20
BRPI0418373A (pt) 2007-05-22
WO2005070393A2 (en) 2005-08-04
UA84903C2 (ru) 2008-12-10
PL1701698T3 (pl) 2008-03-31
US20050152983A1 (en) 2005-07-14
EP1701698A2 (en) 2006-09-20
PE20050683A1 (es) 2005-11-04
EP1701698B1 (en) 2008-01-16
AU2004314213A1 (en) 2005-08-04
CY1107373T1 (el) 2012-12-19
ECSP066757A (es) 2006-11-16
NO20062930L (no) 2006-10-02
PT1701698E (pt) 2008-03-27
KR20060130162A (ko) 2006-12-18
HK1090308A1 (en) 2006-12-22

Similar Documents

Publication Publication Date Title
DK1701698T3 (da) Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
DK2172205T3 (da) Farmaceutisk formulering bestående af lanthan-forbindelser
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
BRPI0511900A (pt) composições farmacêuticas
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
DK1928405T3 (da) Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1601359T3 (da) Væskeformige, farmaceutiske formuleringer af palonosetron
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DK1587478T3 (da) Farmaceutisk sammensætning
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
EP1799271A4 (en) DISPOSAL OF POLYNUCLEOTIDES
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
EP1714648A4 (en) COMBINATION DRUGS
SE0400685D0 (sv) Means for transdermal administration of nicotine
DK1474114T3 (da) Oral doseringsform til reguleret frigivelse af et lægemiddel
PT1752164E (pt) Preparação farmacêutica percutânea para uso externo contendo analgésico anti-inflamatório não esteroide
DK1691808T3 (da) Farmeceutisk sammensætning til oral indgivelse af et pyrazol-3-carboxamid
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
DK1646373T3 (da) Orodispergerbar farmaceutisk sammensætning af en antithrombotisk forbindelse
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante